Amryt Pharma
Clinical trials sponsored by Amryt Pharma, explained in plain language.
-
Hope for tots with rare fat disorder: trial tests lifesaving drug
Disease control Recruiting nowThis study is testing a drug called metreleptin in children under 6 years old who have a rare condition called generalized lipodystrophy, which causes severe problems with fat storage, diabetes, and high blood fats. The main goal is to see if the drug safely lowers blood sugar an…
Phase: PHASE3 • Sponsor: Amryt Pharma • Aim: Disease control
Last updated Mar 31, 2026 12:12 UTC
-
Extended trial tests daily hormone shot for rare fat disorder
Disease control Recruiting nowThis study is a long-term follow-up for people who completed a previous trial of metreleptin, a hormone treatment given as a daily injection under the skin. It aims to monitor the safety and continued effectiveness of the treatment over time in 24 participants with familial parti…
Phase: PHASE3 • Sponsor: Amryt Pharma • Aim: Disease control
Last updated Mar 27, 2026 12:40 UTC
-
Registry launched to track Real-World effects of rare disease drug
Knowledge-focused Recruiting nowThis study is creating a registry to monitor patients who are already taking the drug metreleptin for lipodystrophy, a rare disorder affecting body fat. The goal is to collect long-term safety information on side effects and how well the treatment works in everyday medical practi…
Sponsor: Amryt Pharma • Aim: Knowledge-focused
Last updated Apr 01, 2026 14:41 UTC
-
Five-Year watch: does a Wound-Healing gel change skin cancer odds for Fragile-Skin patients?
Knowledge-focused Recruiting nowThis study aims to understand if using the topical gel Filsuvez affects the risk of developing skin cancers in people with severe forms of Epidermolysis Bullosa (EB), a condition that causes extremely fragile, blistering skin. Researchers will follow about 580 patients with EB fo…
Sponsor: Amryt Pharma • Aim: Knowledge-focused
Last updated Mar 16, 2026 15:25 UTC